SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...

Pivotal trial to support marketing approval of regenerative cells processed with the Celution® System to commence in Q2 2022 SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that the FDA ...

MONTREAL — Mycophenolate mofetil can be substituted for cyclophosphamide for the immunosuppressive treatment of scleroderma-related interstitial lung disease, and might even be safer, according to ...

Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — There is a close temporal link between cancer and the onset of scleroderma in patients with ...

Daval International today announced positive results from its Double-Blind Placebo-Controlled Phase II Clinical Study evaluating the safety and tolerability of AIMSPRO given as a monotherapy to ...

October 23, 2009 (Philadelphia, Pennsylvania) — Imatinib (Gleevec), a drug that has significantly improved survival in chronic myelogenous leukemia and gastrointestinal stromal tumor, is showing ...

A Grand Bahama-based medical facility yesterday unveiled a new treatment for patients with diffuse scleroderma. The Okyanos Center for Regenerative Medicine announced it is offering a new and advanced ...

Scleroderma, or systemic sclerosis refers to a disorder in which the skin and connective tissues of the body start to thicken and harden because of the overproduction of a protein called collagen.

A 65-year-old woman with diffuse scleroderma presented with increasing dyspnea on exertion, fatigue, and approximately a six-week history of palpitations. She had a history of scleroderma-related ...

Localized scleroderma, as the term denotes, is localized to the skin on the hands and face. It is characterized by slow progression and rarely transforms to the systemic type. Localized scleroderma is ...